Fresenius SE & Co. KGaA
http://www.fresenius.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fresenius SE & Co. KGaA
Neurocrine’s Phase II Results In Schizophrenia Mixed, But Enough To Move To Phase III
Competing against Bristol and AbbVie in the muscarinic receptor agonist space, Neurocrine’s drug shows efficacy but a high placebo response and no dose effect.
10 Approvals To Watch Out For In Q3
After a quiet July, August and September are shaping up to be busy on the approvals front. Already this month, the US FDA has approved Adaptimmune’s Teclera for synovial sarcoma, Phathom’s Voquezna for gastro-esophageal reflux disease and Servier’s Voranigo for gliomas. Here, Scrip takes a look at ten other approvals for novel products in the offing for the third quarter.
‘2024 Is The Year Of Financial Progression,’ Says Fresenius As Biosimilars Revenues Jump 102%
With an “attractive biosimilar product portfolio,” Fresenius marked a strong second quarter in its biopharma business, while the generic pharma segment remained flat, but is still “a source of continued success.”
US FDA Calls ’Em Like Its Advisory Committees See Them
So far this year, when the agency has taken action on NMEs that went before advisory committees, the FDA decision has matched the committee vote.
Company Information
- Industry
- Distributors
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
- Services
- Other Names / Subsidiaries
-
- APP Pharmaceuticals, Inc.
- Asia Renal Care Ltd.
- Fresenius Kabi Pharmaceuticals Holding, Inc.
- Fresenius Medical Care
- Fresenius Medical Group AG
- Vifor-Fresenius Medical Care Renal Pharma Ltd. (VFMCRP)
- Xenios AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice